Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

10.88 -0.02 (-0.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,719,732
Open 10.78
Bid (Size) 10.60 (2)
Ask (Size) 11.15 (20)
Prev. Close 10.90
Today's Range 10.51 - 10.91
52wk Range 8.060 - 13.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Via Benzinga
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure... 
Via Benzinga

Performance

YTD
-4.14%
-4.14%
1 Month
+7.94%
+7.94%
3 Month
+3.42%
+3.42%
6 Month
+28.76%
+28.76%
1 Year
+25.93%
+25.93%

More News

Read More
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
Via Investor's Business Daily
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
From Roivant Sciences
Via GlobeNewswire
Where Roivant Sciences Stands With Analysts
Via Benzinga
The Analyst Landscape: 4 Takes On Roivant Sciences
Via Benzinga
Roivant Sciences Earnings Preview
Via Benzinga
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase
Via Investor's Business Daily
5 Value Stocks In The Healthcare Sector
Via Benzinga
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Analyst Ratings for Roivant Sciences
Via Benzinga
8 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Earnings Scheduled For February 13, 2024
Via Benzinga
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
From Roivant Sciences
Via GlobeNewswire
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
Via Investor's Business Daily
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Via Benzinga
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Via Benzinga
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Via Benzinga
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
From Roivant Sciences
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.